Royal Marsden Nhs Foundation Trust

This early-stage study tested whether adding a short, high-dose course of targeted radiation (SBRT) to a standard immunotherapy drug (pembrolizumab) was safe for people with advanced non-small cell lung cancer. The goal was to see if the radiation could help the immunotherapy wor…

This early-stage study aimed to find a safe dose for combining a new immunotherapy drug (pembrolizumab) with standard chemotherapy and radiation for patients with advanced head and neck cancer. It focused on measuring side effects, especially skin and mouth reactions, in a small …

This early-stage study tested whether combining a targeted, high-dose radiation (SBRT) with an immunotherapy drug (pembrolizumab) was safe and effective for patients with advanced, inoperable pleural mesothelioma whose cancer had progressed after initial chemotherapy. The trial w…